EUVIMEDEUVIMED entdecken
Fallbericht

A Case of Complete Remission of Glucocorticoid-Dependent Nephrotic Syndrome after Targeted-Release Formulation of Budesonide Treatment in a Patient with Mild Mesangial Proliferative IgA Nephropathy

Efstathios Mitsopoulos, Panagiotis Pateinakis, Christodoulos Keskinis, Dorothea Papadopoulou

Nephron · 2024

DOI: 10.1159/000543271 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Nephron, 2024. Verfasst von Efstathios Mitsopoulos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, General Hospital of Thessaloniki "Papageorgiou", Thessaloniki, Greece. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Budesonide, Nephrotic Syndrome, Glucocorticoids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of nephrotic syndrome with mild histopathological lesions of IgA nephropathy is considered by some as a special form of IgA nephropathy with superimposed minimal change disease (MCD) while by others as a coincidental deposition of IgA in patients with MCD (MCD-IgAN). We present the first case of complete remission of nephrotic syndrome in a 55-year-old man with MCD-IgAN after the administration of a targeted-release formulation of budesonide (TRF-budesonide). The patient’s treatment with TRF-budesonide, even though methylprednisolone, mycophenolate mofetil, and cyclophosphamide had been previously tried, is of particular importance because it not only suggests that TRF-budesonide appears to be a promising treatment for MCD-IgAN but may also provide a new therapeutic option for patients with podocytopathies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGABudesonideNephrotic SyndromeGlucocorticoidsHumansMaleMiddle AgedRemission InductionDelayed-Action PreparationsNephrosis, Lipoid

Stichwörter der Autor:innen

IgA nephropathyMinimal change diseaseNephrotic syndromeTargeted-release formulation of budesonide

Substanzen

BudesonideGlucocorticoidsDelayed-Action Preparations

Autor:innen und Institutionen

  • Department of Nephrology, General Hospital of Thessaloniki "Papageorgiou", Thessaloniki, Greece.

Zitieren

APA

Mitsopoulos, E., Pateinakis, P., Keskinis, C., & Papadopoulou, D. (2024). A Case of Complete Remission of Glucocorticoid-Dependent Nephrotic Syndrome after Targeted-Release Formulation of Budesonide Treatment in a Patient with Mild Mesangial Proliferative IgA Nephropathy. Nephron. https://doi.org/10.1159/000543271

Vancouver

Mitsopoulos E, Pateinakis P, Keskinis C, Papadopoulou D. A Case of Complete Remission of Glucocorticoid-Dependent Nephrotic Syndrome after Targeted-Release Formulation of Budesonide Treatment in a Patient with Mild Mesangial Proliferative IgA Nephropathy. Nephron. 2024. doi:10.1159/000543271

BibTeX
@article{Mitsopoulos2024,
  author = {Mitsopoulos, Efstathios and Pateinakis, Panagiotis and Keskinis, Christodoulos and Papadopoulou, Dorothea},
  title = {A Case of Complete Remission of Glucocorticoid-Dependent Nephrotic Syndrome after Targeted-Release Formulation of Budesonide Treatment in a Patient with Mild Mesangial Proliferative IgA Nephropathy},
  journal = {Nephron},
  year = {2024},
  doi = {10.1159/000543271}
}
Kostenlos starten →